# US 2025/0082698 A1 · Bacterial compositions for treating and preventing halitosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082698 A1
- Document ID: US20250082698A1
- Status: Published application
- Kind: A1
- Application number: 18/884,680
- Filed: 2024-09-13
- Published: 2025-03-13
- Earliest claimed: 2023-09-13
- Assignees: Imvela Corp.
- Applicants: Imvela Corp.
- Inventors: Raphaël Turcotte; Ravi Sheth
- Web page: https://patentgrep.com/patent/US20250082698A1

## CPC

- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/02: Algae
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)

## Abstract

Some aspects of the disclosure relate to compositions comprising bacterial strains capable of reducing volatile sulfur compounds (VSCs) in an environment, nutritional supplements containing such bacterial strains, and methods of production and use thereof.

## Claims

### Claim 1

A nutritional supplement comprising a bacterial mixture and a carrier, the bacterial mixture comprising:
(i) a first bacterial strain comprising a 16S rDNA sequence with at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 1; and
(ii) one or more additional bacterial strains selected from the group consisting of:
(a) a second bacterial strain comprising a 16S rDNA sequence with at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 2; and
(b) a third bacterial strain that is different from the second bacterial strain and comprises a 16S rDNA sequence with at least 97% sequence identity to the nucleotide sequence of SEQ ID NO: 3,
wherein each of the bacterial strains is in powder form.

### Claim 2 (depends on 1)

The nutritional supplement of claim 1, wherein the bacterial mixture comprises the second bacterial strain and the third bacterial strain, wherein:
(1) the first bacterial strain reduces abundance of one or more volatile sulfur compounds (VSCs);
(2) the second bacterial strain enhances the reduction in abundance of one or more VSCs by the first bacterial strain; and/or
(3) the third bacterial strain reduces pH of an oral microenvironment of a subject to a value less than 7.5.

### Claim 3 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement comprises a fiber and/or a starch.

### Claim 4 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement comprises maltodextrin.

### Claim 5 (depends on 3)

The nutritional supplement of claim 3, wherein the nutritional supplement comprises tapioca and/or a fiber selected from the group consisting of sugar beet pulp, chicory pulp, chicory, coconut endosperm fiber, wheat fiber, fructooligosaccharides, galactooligosaccharides, and inulin.

### Claim 6 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement is in the form of powder meal topper.

### Claim 7 (depends on 1)

The nutritional supplement of claim 1, wherein each of the bacterial strains is lyophilized or spray-dried.

### Claim 8 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement comprises a dried algae.

### Claim 9 (depends on 8)

The nutritional supplement of claim 8, wherein the nutritional supplement comprises a dried algae selected from the group consisting of Ascophyllum nodosum, Spirulina, Chlorella, Ulva lactuca, Laminaria digitata and Fucus vesiculosus.

### Claim 10 (depends on 1)

The nutritional supplement of claim 1, wherein:
the first bacterial strain comprises a 16S rDNA sequence with at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 1;
the second bacterial strain comprises a 16S rDNA sequence with at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 2; and
the third bacterial strain comprises a 16S rDNA sequence with at least 99% sequence identity to the nucleotide sequence of SEQ ID NO: 3.

### Claim 11 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement comprises an antioxidant selected from the group consisting of vitamin A, vitamin C, vitamin E, green tea polyphenol, tannins, resveratrol, flavonoids, anthrocyanins, indoleacrylic acid, indolepropionic acid, indole-3-carbinol, indoleacrylic acid, indolelactic acid, indoleacetic acid indolepyruvic acid, tryptophol, and Coenzyme Q10.

### Claim 12 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement comprises 1×105 to 1×1010 colony forming units (CFUs) of each of the bacterial strains.

### Claim 13 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement treats or prevents one or more symptoms of halitosis in a subject.

### Claim 14 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement reduces abundance of one or more VSCs in an oral cavity of a subject.

### Claim 15 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement reduces abundance of one or more microorganisms that produce one or more VSCs in an oral cavity of a subject.

### Claim 16 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement treats or prevents one or more symptoms of oral inflammation in a subject.

### Claim 17 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement reduces abundance of or prevents formation of gingivitis, plaque, tartar, and/or dental calculus in a subject.

### Claim 18 (depends on 13)

The nutritional supplement of claim 13, wherein the subject is a dog or cat.

### Claim 19 (depends on 1)

The nutritional supplement of claim 1, wherein the nutritional supplement, wherein the nutritional supplement comprises a grain selected from the group consisting of wheat, corn, rice, oats, and barley.

### Claim 20 (depends on 1)

The nutritional supplement of claim 1 wherein the nutritional supplement comprises a meat and/or animal-derived material.
